Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Daewoong Pharmaceutical Reports Promising Phase 1 Results for Autoimmune Drug Candidate Plodicitinib

Daewoong Pharmaceutical is advancing the development of its next-generation autoimmune disease treatment candidate, Plodicitinib, following encouraging interim results from its Phase 1 clinical trial.The company announced on November 17 that it presented interim findings from the Phase 1 study of Plodicitinib (DWP212525), an oral investigational drug for autoimmune and inflammatory diseases, at…

Daewoong Pharmaceutical presented promising interim results from its Phase 1 clinical trial of Plodicitinib, a next-generation drug candidate for autoimmune diseases, at ACR Convergence 2026, the American College of Rheumatology's annual meeting in Orlando, Florida. The single-ascending-dose study involved 44 healthy adult volunteers, with the maximum target occupancy for key immune proteins exceeding 90%.

The drug showed a favorable safety profile, with no serious adverse events reported during the trial. Plodicitinib targets three immune signaling proteins - JAK3, ITK, and BTK - which regulate immune cell activity. By inhibiting all three pathways simultaneously, the drug aims to address multiple components of excessive immune responses, offering potential applications in various autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome.

Daewoong Pharmaceutical's CEO, Park Sung-soo, highlighted the high target occupancy as a significant milestone for the drug's continued development and plans to use upcoming clinical findings to assess the candidate's potential as a treatment for autoimmune and inflammatory diseases.

Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at koreaittimes.com →

More in Health & Medicine

More from Tuesday 17 November →